Drs. Eric D. Donnenfeld and Preeya K. Gupta define acute exacerbations of dry eye disease as flares and discuss the impact of dry eye flares on a patient’s quality of life as well as surgical outcomes. This is Part 1 of 3.
This activity is supported by an unrestricted educational grant from Kala Pharmaceuticals.
There is no credit associated with this podcast.
In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.
Course Viewing Requirements
Supported Browsers: Internet Explorer 11 for Windows Edge (recent versions; Chromium-based) for Windows Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux Safari (recent versions) for Mac OSX, or iOS
Hardware Requirements: 4GB+ RAM
Recommended internet speed 5Mbps+
Preeya K. Gupta, MD
Founder and Director of Triangle Eye Consultants
Wake Forest and Cary, North Carolina
Eric D. Donnenfeld, MD
Ophthalmic Consultants of Long Island and Connecticut
Trustee, Dartmouth Medical School
Clinical Professor of Ophthalmology
New York University
New York, New York
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.
The following faculty/staff members have the following financial relationships with commercial interests:
Preeya K. Gupta, MD, has no financial agreements with commercial interests.
Eric D. Donnenfeld, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allegro, Allergan , Alcon Vision, Avellino Labs, Bausch + Lomb, Carl Zeiss Meditec, CorneaGen, Covalent, BVI, Blephex, Dompé, ELT Sight, EyePoint Pharma, Foresight, Glaukos, Ivantis, Johnson & Johnson Vision, Kala Pharmaceuticals, Katena, Lacripen, LensGen, Mati Therapeutics, MDBackline, Merck, Mimetogen, Nanowafer, Novabay, Novartis, Novaliq, Ocular Innovations, Oculis, Odyssey, Omega Ophthalmics, Oyster Point Pharma, Pfizer, Pogotec, Ocuhub, Omeros, PRN, RegenerEyes, ReTear, RPS, Shire, Strathspey Crown, Sun Pharma, Surface, Tarsus, Tearlab, Tearscience, Thea, TLC Laser Centers, Veracity, Versant Ventures, Visionary Venture, and Visus Therapeutics. Stock/Shareholder: Avedro, CorneaGen, Covalent, ELT Sight, EyePoint Pharma Glaukos, Ivantis, Lacripen, LensGen, Mati Therapeutics, MDBackline, Mimetogen, Novabay, Ocuhub, Ocular Innovations Oculis, Orasis Pogotec, RegenerEyes, ReTear, RPS , Strathspey Crown, Surface, Tarsus, Tearlab, Veracity, Versant Ventures, Visionary Ventures, and Visus Therapeutics.
EDITORIAL SUPPORT DISCLOSURES The staff and planners from Evolve and The Fundingsland Group have no financial relationships with commercial interests. Nisha Mukherjee, MD, peer reviewer, has no financial relationships with commercial interests.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, The Fundingsland Group, or Kala Pharmaceuticals.
Release Date:
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Yewlin E. Chee, MD
Camila Ventura MD, PhD
Edward Wood, MD
Tony Capone Jr, MD
Katherine E. Talcott, MD
Nassim Abreu, MD
Janis T. Eells, Ph.D.
David Boyer, MD
Diana V. Do, MD
Marion Munk, MD, Ph.D
